Citadel Advisors’s XBiotech XBIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-18,400
Closed -$44K 14378
2025
Q4
$44K Buy
+18,400
New +$45.4K ﹤0.01% 12093
2025
Q1
Sell
-200
Closed -$790 15708
2024
Q4
$790 Buy
+200
New +$1.36K ﹤0.01% 14270
2024
Q3
Sell
-5,800
Closed -$29.8K 15378
2024
Q2
$29.8K Sell
5,800
-500
-8% -$3.86K ﹤0.01% 12280
2024
Q1
$51.2K Buy
6,300
+5,500
+688% +$31.5K ﹤0.01% 12155
2023
Q4
$3.2K Buy
800
+700
+700% +$2.79K ﹤0.01% 13619
2023
Q3
$412 Sell
100
-1,800
-95% -$9.01K ﹤0.01% 14064
2023
Q2
$11.3K Buy
+1,900
New +$8.57K ﹤0.01% 13153
2023
Q1
Sell
-1,900
Closed -$6.67K 15607
2022
Q4
$6.67K Buy
+1,900
New +$6.48K ﹤0.01% 13898
2021
Q3
Sell
-16,100
Closed -$267K 14766
2021
Q2
$267K Buy
+16,100
New +$273K ﹤0.01% 11552
2021
Q1
Sell
-15,900
Closed -$249K 13791
2020
Q4
$249K Sell
15,900
-6,500
-29% -$120K ﹤0.01% 9407
2020
Q3
$428K Buy
+22,400
New +$387K ﹤0.01% 7552
2018
Q3
Sell
-15,800
Closed -$71K 9759
2018
Q2
$71K Buy
15,800
+4,800
+44% +$21.7K ﹤0.01% 8362
2018
Q1
$59K Buy
+11,000
New +$50.7K ﹤0.01% 7882
2017
Q3
Sell
-30,300
Closed -$142K 8129
2017
Q2
$142K Buy
30,300
+14,300
+89% +$137K ﹤0.01% 6780
2017
Q1
$264K Buy
+16,000
New +$209K ﹤0.01% 6077

Other funds holding XBIT

Citadel Advisors's XBIT Position: Q4 2025 in Review

Citadel Advisors sold out of XBiotech (XBIT) in Q4 2025, closing a stake of 42,816 shares — an estimated $106K sold.

Citadel Advisors first reported a position in XBIT in Q2 2017 and held it in 17 quarters. The position peaked at $619K in Q3 2021. 41 funds tracked by Wall St. Rank hold XBIT as of Q4 2025.

  • Citadel Advisors reported no remaining XBiotech position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 42,816 XBiotech shares in Q4 2025, an estimated $106K.
  • Citadel Advisors first reported a position in XBiotech in Q2 2017 and held it in 17 quarters.
  • Citadel Advisors's XBiotech position peaked at $619K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held XBiotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.